Xiaolin Sang
Overview
Explore the profile of Xiaolin Sang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sang X, Han J, Wang Z, Cai W, Liao X, Kong Z, et al.
Oncogene
. 2024 Sep;
43(45):3335-3347.
PMID: 39306614
High-grade serous ovarian cancer (HGSOC) is a highly aggressive disease often developing resistance to current therapies, necessitating new treatment strategies. Our study identifies SGK1, a key effector in the PI3K...
2.
Jia Y, Wang M, Sang X, Liu P, Gao J, Jiang K, et al.
Front Oncol
. 2022 Feb;
11:812264.
PMID: 35155204
While PARP inhibitor (PARPi) therapies have shown promising results in the treatment of high-grade serous ovarian cancer (HGSOC) harboring homologous recombination deficiencies, primary resistance to PARPi frequently occurs and even...
3.
Liu Z, Sang X, Wang M, Liu Y, Liu J, Wang X, et al.
Oncogene
. 2021 Sep;
40(44):6273-6283.
PMID: 34556812
Complete blockade of the HER2 protein itself and HER signaling network is critical to achieving effective HER2-targeted therapies. Despite the success of HER2-targeted therapies, the diseases will relapse in a...
4.
Sang X, Li L, Rui C, Liu Y, Liu Z, Tao Z, et al.
Cancer Lett
. 2021 Jun;
518:82-93.
PMID: 34153400
Despite HER2-targeted cancer treatments have provided considerable clinical benefits, resistance to HER2-targeted agents will inevitably develop. Targeting non-oncogene vulnerabilities including endoplasmic reticulum (EnR) stress has emerged as an attractive alternative...
5.
Zhang Y, Gao X, Yi J, Sang X, Dai Z, Tao Z, et al.
Cell Death Dis
. 2021 Jan;
12(1):12.
PMID: 33414468
High levels of Basic Transcription Factor 3 (BTF3) have been associated with prostate cancer. However, the mechanisms underlying the role of BTF3 as an oncogenic transcription factor in prostate tumorigenesis...
6.
Wang M, Xue Y, Shen L, Qin P, Sang X, Tao Z, et al.
Redox Biol
. 2019 May;
24:101225.
PMID: 31136958
Cervical cancer has poor prognosis and patients are often diagnosed at advanced stages of the disease with limited treatment options. There is thus an urgent need for the discovery of...
7.
Zhang S, Sang X, Hou D, Chen J, Gu H, Zhang Y, et al.
Biomaterials
. 2019 May;
210:83-93.
PMID: 31078314
Chronic infection with hepatitis B virus (HBV) is a major public health problem. Recently, RNA interfering-based strategy has shown great potential to eradicate HBV infection. In current study, we report...
8.
Yi J, Liu C, Tao Z, Wang M, Jia Y, Sang X, et al.
EBioMedicine
. 2019 Mar;
43:225-237.
PMID: 30898650
Background: While PARP inhibitors and CDK4/6 inhibitors, the two classes of FDA-approved agents, have shown promising clinical benefits, there is an urgent need to develop new therapeutic strategies to improve...
9.
Ding J, Wang X, Zhang Y, Sang X, Yi J, Liu C, et al.
Cancer Lett
. 2018 Oct;
440-441:54-63.
PMID: 30315845
Selective phosphatidylinositol 3 kinase (PI3K) inhibitors are being actively tested in clinical trials for ERα-positive (ER+) breast cancer due to the presence of activating PIK3CA mutations. However, recent studies have...
10.
Hou D, He F, Ma L, Cao M, Zhou Z, Wei Z, et al.
J Nutr Biochem
. 2018 May;
57:197-205.
PMID: 29751293
MicroRNAs have become the spotlight of the biological community for more than a decade, but we are only now beginning to understand their functions. The detection of stably expressed endogenous...